retapamulin

a synthetic pleuromutilin

Also Known As:

Altabax; Altargo; SB 275833; SB-275833; SB275833; acetic acid, 2-(((3-exo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester

Networked: 52 relevant articles (13 outcomes, 11 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - retapamulin: 52
Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - retapamulin: 52

Experts

1.	Dalessandro, Marybeth: 3 articles (12/2014 - 09/2008)
2.	Hebert, Adelaide A: 2 articles (06/2021 - 02/2015)
3.	Andriessen, Anneke: 2 articles (01/2021 - 07/2019)
4.	Li, Gang: 2 articles (12/2014 - 02/2009)
5.	Scangarella-Oman, Nicole E: 2 articles (12/2014 - 04/2009)
6.	Shawar, Ribhi M: 2 articles (04/2009 - 09/2008)
7.	Shawar, Ribhi: 2 articles (02/2009 - 01/2007)
8.	Twynholm, Monique: 2 articles (02/2009 - 01/2007)
9.	Parish, Lawrence Charles: 2 articles (02/2008 - 12/2006)
10.	Keam, Susan J: 2 articles (01/2008 - 01/2008)

Related Diseases

1.	Impetigo (Impetigo Contagiosa) 05/01/2008 - "This study shows that topical retapamulin is effective and safe in the treatment of primary impetigo, offering a new treatment option." 06/01/2021 - "Retapamulin is indicated for lesions of impetigo that are colonized by MSSA and streptococcus S. " 10/01/2008 - "Here we consider the place of retapamulin in impetigo and its other licensed indications." 10/01/2007 - "Altabax approved to treat impetigo." 01/01/2007 - "Retapamulin is a highly effective and convenient new treatment option for impetigo, with efficacy against isolates resistant to existing therapies."
2.	Infections 08/01/2018 - "Topical retapamulin is to be well-tolerated and effective in patients with bacterial skin infections of locally approved prescribing information." 02/01/2008 - "In preclinical studies, retapamulin demonstrated pronounced in vitro activity against staphylococcal, streptococcal and anaerobic Gram-positive clinical isolates associated with skin and skin structure infections. " 07/01/2012 - "Twice-daily application of retapamulin 1% produced a mean 8.1-point reduction from baseline in the mean Skin Infection Rating Scale score. " 10/01/2009 - "In 2007, Retapamulin, as the first in a new class of topical antibacterial in the nearly two decades, was approved for use in human skin infections. " 04/01/2007 - "Pending further clinical investigation, retapamulin may offer an alternative treatment for anaerobic skin infections in this era of increasing resistance."
3.	Dermatitis 02/01/2008 - "In clinical efficacy trials involving pediatric and adult patients who received retapamulin twice daily for five days, retapamulin was highly effective in the treatment of impetigo, secondarily infected traumatic lesions and secondarily infected dermatitis. " 07/01/2014 - "The authors hypothesized that retapamulin 1% ointment and clobetasol propionate 0.05% foam would decrease disease severity in subjects with hand/foot dermatitis and provide a higher clearance of Staphylococcus aureus colonization, when compared to vehicle (placebo) ointment and clobetasol propionate 0.05% foam. " 01/01/2010 - "Clinical studies exploring the treatment of secondarily infected dermatitis reveal that the efficacy of topical retapamulin is comparable to a 10-day course of oral cephalexin or to topical fusidic acid. " 07/01/2014 - "At Day 15, retapamulin 1% ointment with clobetasol propionate 0.05% foam was more efficacious than vehicle ointment and clobetasol propionate 0.05% foam for disease improvement and Staphylococcus aureus clearance in adult subjects with hand/foot dermatitis." 07/01/2014 - "Adult subjects with moderate to very severe hand/foot dermatitis had twice-daily topical application of clobetasol propionate 0.05% foam to hands/feet for 14 days and were randomized to apply either retapamulin 1% ointment or vehicle ointment twice daily to hands/feet and nares for five days. "
4.	Abscess 01/01/2008 - "In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cephalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. " 01/01/2008 - "In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cefalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. " 01/01/2008 - "In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions, or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. " 01/01/2008 - "In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. " 12/01/2014 - "To evaluate the clinical and bacteriological efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of patients with secondarily infected traumatic lesions (SITLs; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA). "
5.	Soft Tissue Infections 05/01/2014 - "Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children." 02/01/2015 - "Prospective, nonrandomized, uncontrolled, open label, single center trial conducted between April 2008 and November 2012 that evaluated efficacy of retapamulin ointment 1% in the treatment of impetigo, folliculitis, and other minor soft tissue infections in children and adults. " 01/01/2020 - "To find a therapeutic alternative for the treatment of skin and soft tissue infections, we evaluated the effects of combinations of retapamulin with macrolide, lincosamide, and streptogramin (MLS) antibiotics against Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecium, and Enterococcus faecalis. " 09/01/2016 - "Susceptibility studies were performed against bacterial isolates (110 total from 2004 to 2013; primarily from skin and soft tissue infections) selected for elevated MIC values (non-wildtype [WT] distributions) to bacitracin, polymyxin B, neomycin, mupirocin, retapamulin, fusidic acid, or gentamicin. "

Related Drugs and Biologics

1.	Ointments (Pastes)
2.	Cephalexin (Cefalexin)
3.	Methicillin (Metin)
4.	Fusidic Acid (Fucithalmic)
5.	Linezolid (Zyvox)
6.	Clobetasol (Clobetasol Propionate)
7.	Anti-Bacterial Agents (Antibiotics)
8.	Mupirocin (Bactroban)
9.	Gentamicins (Gentamicin)
10.	Azithromycin (Zithromax)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Stents
4.	Mass Drug Administration